Primary series COVID-19 vaccine effectiveness among healthcare workers in Albania, February-December 2021.
Albania
COVID-19 vaccine
Delta variant
Healthcare workers
Hybrid immunity
Vaccine effectiveness
Journal
IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
15
01
2023
revised:
09
04
2023
accepted:
11
04
2023
medline:
15
6
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
Healthcare workers have experienced high rates of morbidity and mortality from coronavirus disease 2019 (COVID-19). A prospective cohort study was conducted in three Albanian hospitals between 19 February and 14 December 2021. All participants underwent polymerase chain reaction (PCR) and serological testing at enrolment, regular serology throughout, and PCR testing when symptomatic.Vaccine effectiveness (VE) against COVID-19 and against all severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections (symptomatic or asymptomatic) was estimated. VE was estimated using a Cox regression model, with vaccination status as a time-varying variable. In total, 1504 HCWs were enrolled in this study; 70% had evidence of prior SARS-CoV-2 infection. VE was 65.1% [95% confidence interval (CI) 37.7-80.5] against COVID-19, 58.2% (95% CI 15.7-79.3) among participants without prior SARS-CoV-2 infection, and 73.6% (95% CI 24.3-90.8) among participants with prior SARS-CoV-2 infection. For BNT162b2 alone, VE was 69.5% (95% CI 44.5-83.2). During the period when the Delta variant was predominant, VE was 67.1% (95% CI 38.3-82.5). VE against SARS-CoV-2 infection for the full study period was 36.9% (95% CI 15.8-52.7). This study found moderate primary series VE against COVID-19 among healthcare workers in Albania. These results support the continued promotion of COVID-19 vaccination in Albania, and highlight the benefits of vaccination in populations with high levels of prior infection.
Sections du résumé
Background
UNASSIGNED
Healthcare workers have experienced high rates of morbidity and mortality from coronavirus disease 2019 (COVID-19).
Methods
UNASSIGNED
A prospective cohort study was conducted in three Albanian hospitals between 19 February and 14 December 2021. All participants underwent polymerase chain reaction (PCR) and serological testing at enrolment, regular serology throughout, and PCR testing when symptomatic.Vaccine effectiveness (VE) against COVID-19 and against all severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections (symptomatic or asymptomatic) was estimated. VE was estimated using a Cox regression model, with vaccination status as a time-varying variable.
Findings
UNASSIGNED
In total, 1504 HCWs were enrolled in this study; 70% had evidence of prior SARS-CoV-2 infection. VE was 65.1% [95% confidence interval (CI) 37.7-80.5] against COVID-19, 58.2% (95% CI 15.7-79.3) among participants without prior SARS-CoV-2 infection, and 73.6% (95% CI 24.3-90.8) among participants with prior SARS-CoV-2 infection. For BNT162b2 alone, VE was 69.5% (95% CI 44.5-83.2). During the period when the Delta variant was predominant, VE was 67.1% (95% CI 38.3-82.5). VE against SARS-CoV-2 infection for the full study period was 36.9% (95% CI 15.8-52.7).
Interpretation
UNASSIGNED
This study found moderate primary series VE against COVID-19 among healthcare workers in Albania. These results support the continued promotion of COVID-19 vaccination in Albania, and highlight the benefits of vaccination in populations with high levels of prior infection.
Identifiants
pubmed: 37317681
doi: 10.1016/j.ijregi.2023.04.009
pii: S2772-7076(23)00051-6
pmc: PMC10106115
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19-27Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCIRD CDC HHS
ID : U38 IP000873
Pays : United States
Informations de copyright
© 2023 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Déclaration de conflit d'intérêts
None declared.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet Infect Dis. 2023 May;23(5):556-567
pubmed: 36681084
Vaccines (Basel). 2023 Apr 24;11(5):
pubmed: 37242996
China CDC Wkly. 2021 Dec 3;3(49):1049-1051
pubmed: 34934514
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Sci Rep. 2022 Mar 25;12(1):5156
pubmed: 35338237
Euro Surveill. 2021 Nov;26(47):
pubmed: 34823641
BMJ Glob Health. 2020 Dec;5(12):
pubmed: 33277297
JAMA Netw Open. 2022 Jan 4;5(1):e2142725
pubmed: 35015067
BMJ Open. 2022 Mar 23;12(3):e057741
pubmed: 35321895
Int J Nurs Stud. 2022 May;129:104211
pubmed: 35278750
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
N Engl J Med. 2021 May 6;384(18):1775-1777
pubmed: 33755373
Lancet. 2023 Mar 11;401(10379):833-842
pubmed: 36930674
JAMA. 2021 Jun 22;325(24):2500-2502
pubmed: 33956050
Lancet Infect Dis. 2022 Jun;22(6):791-801
pubmed: 35366959
Lancet Microbe. 2020 Nov;1(7):e283-e289
pubmed: 33015652
N Engl J Med. 2022 Jun 9;386(23):2201-2212
pubmed: 35613036
J Am Board Fam Med. 2021 Feb;34(Suppl):S244-S246
pubmed: 33622846
Lancet Infect Dis. 2022 Jun;22(6):781-790
pubmed: 35366962